The PAM50 test, designed to determine a risk of recurrence (ROR) score for patients with Breast cancer, adds significant prognostic information to clinical decision making and might be superior to other risk assays, findings from two recent studies indicate.
The assay is based on the PAM50 gene signature, which measures expression profiles for 50 genes and classifies tumors into four intrinsic subtypes
- luminal A
- luminal B
An algorithm is then used to combine the gene signature, intrinsic subtype, tumor size, and proliferation score.